Panacea gets US Patent nod for Thank God: related news

Panacea gets US Patent nod for `Thank God`

Panacea Biotec has been granted a patent from US Patent & Trademark Office for their product Thank God (Euphorbia Prostrata) for effective management of hemorrhoids and piles. With this, the company is looking forward to launch this product in high potential market of US and EU. As per current industry trends, the total potential of anti-hernorrhoids and piles market in US and EU is between US$500-600mn.

Panacea Biotec receives US Patent for "Thank God"

Panacea Biotec, India's leading research based Health Management Company involved in research, manufacturing and marketing of branded pharmaceutical formulations, vaccines and natural products has been granted a patent from US Patent & Trademark Office for their product Thank God (Euphorbia Prostrata) for effective management of hemorrhoids & piles (Patent No. 7,371,412 B2).

Panacea Biotec gets U.S. patent

MUMBAI: Leading biotechnology firm Panacea Biotec on Wednesday said that it has received U.S. patent for ‘Thank God’ drug used in treating piles. The U.S. Patent and Trademark Office has granted patent for ‘Thank God’ drug which is used for treating hemorrhoids and piles.

EntreMed receives new patent for 2-Methoxyestradiol analogs

Add our medical news to digg - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to NewsVine - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Fark - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Furl - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Shadows - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to YahooMyWeb - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Reddit -EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to StumbleUpon - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Facebook - EntreMed receives new patent for 2-Methoxyestradiol analogs

Supreme Court strengthens patent exhaustion doctrine

The United States Supreme Court has unanimously held in Quanta Computer, Inc. v. LG Electronics, Inc. that the patent law cannot be used to control the subsequent use or disposition of a product "that substantially embodies a patent" once the product has been sold with authority of the patent owner. "The authorized sale of an article that substantially embodies a patent exhausts the patent holder's rights and prevents the patent holder from invoking the patent law to control post-sale use of the article." Patent exhaustion applies whether the patents are directed to products or methods. "Our precedents do not differentiate transactions involving embodiments of patented methods or processes from those involving patented apparatuses or materials.

Drugs industry protecting 'morally unacceptable' patent system

Add our medical news to digg - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to NewsVine - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Fark - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Furl - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Shadows - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to YahooMyWeb - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Reddit -Drugs industry protecting 'morally unacceptable' patent system Add our medical news to StumbleUpon - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Facebook - Drugs industry protecting 'morally unaccep

U.S. Patent on Cytori's Celution System Technology Issued; Celution System Commercialization not Impacted by Recent 6,777,231 Patent Inventorship Decision

SAN DIEGO--(BUSINESS WIRE)--Jun 24, 2008 - U.S. Patent No. 7,390,484 ("the '484 patent") covering Cytori's (NASDAQ:CYTX) Celution(R) System technology was issued today by the United States Patent and Trademark Office. The '484 patent provides Cytori critical market protection for its commercialization of the Celution System in the United States, where the Company is seeking regulatory approval. The '484 patent also protects Cytori's rights to manufacture the Celution Systems in the United States for commercialization into all markets, including Europe and Asia-Pacific, where the device is currently being sold. Other related patent filings are in progress around the globe.

Cosmo Pharmaceuticals awarded US patent for use of its MMX technology

Lainate, Italy – August 4, 2008 – Cosmo Pharmaceuticals, (SWX:COPN) a specialty pharma company that aims to become a global leader in optimised therapies for certain Gastrointestinal (GI) diseases, announced today that the US Trademark and Patent Office has issued a “notice of allowance” for its “controlled release and taste masking oral pharmaceutical compositions” better known as the MMX™ technology patent. This patent will expire in 2020, not considering possible SPCs. The patent was previously granted in Europe in 2003 and in other countries outside the US.

JPEG Patent's Single Claim Rejected (And Smacked Down For Good Measure)

We've been covering the ongoing saga of an old patent we've referred to as the "JPEG Patent." This actually isn't the first patent we've called the JPEG Patent, because multiple people claimed to hold patents over the technology that goes into a JPEG image. But, this one was rather special. The patent had been used, repeatedly, by lawyer Ray Niro, against a wide range of opponents, including a patent system critic. The end result was a drawn out review process where all of the original claims were rejected, but a single new claim was added to the patent, which Niro insisted covered JPEGs on a website.

Silence Therapeutics Announces Successful Opposition of Glover Patent

a leading European RNA interference (RNAi) focused biotechnology company, announced today the successful opposition of a fundamental Alnylam Pharmaceuticals, Inc. European patent resulting in the patent being revoked in its entirety. The Opposition Division of the European Patent Office, following a three day hearing, announced its decision to revoke European Patent EP 1 230 375, exclusively licensed to Alnylam Pharmaceuticals from Cancer Research Technology, Ltd (UK). The Patent, commonly referred to as the "Glover" patent, broadly relates to medicaments comprising an RNA interference mediating RNA molecule. Opposition briefs to the Glover patent had been filed by Silence Therapeutics AG, Sanofi-Aventis Deutschland GmbH, Quark Biotech, Inc.

Midatech announces priority nanoparticle patent granted by US

Midatech Group has received a US grant on its proprietary patent application (US09,622253), protecting the Company's novel nanoparticle technology. The US Patent Office has issued allowance of 121 claims, placing Midatech as the global leader in nanotechnology for biological applications, according to the company. Equivalent patent applications have previously been granted in Australia (AU2001294068) and Europe (EP1326589B).

Midatech Announces Priority Nanoparticle Patent Granted by US

Oxford, 4th August 2008- Midatech Group, a world leader in the production and application of synthetically produced nanoparticles, has received a US grant on its proprietary patent application (US09,622253), protecting the Company’s novel nanoparticle technology. The US Patent Office has issued allowance of 121 claims, placing Midatech as the global leader in nanotechnology for biological applications. Equivalent patent applications have previously been granted in Australia (AU2001294068) and Europe (EP1326589B).

Tech Companies Team Up To Buy Up Patents To Keep Them Away From Others

Google, Verizon, HP, Cisco and some others are apparently teaming up to put money towards buying patents to keep them out of the hands of patent hoarders who would turn around and sue them. This isn't a new concept, and has been tried before -- and it didn't help much. The problem is that many of the worst patent suits aren't from "known" patents, but someone claiming a patent on some minor feature that everyone thought was obvious. Also, this type of action only encourages more bad patent activities by adding another buyer to the market. Now, questionable patent holders will recognize that they can also just sell to this patent pool, rather than selling to some patent hoarding firm. This is one of those ideas that sounds good on paper, but will have little to no effect on slowing down or stopping bad patent lawsuits, and may actually enc

PATENT REFORM IS NOT NECESSARY

Virtually all of the problems of the U.S. Patent system, including the high cost of obtaining a patent can be attributed to examiners issuing improper "bogus" rejections. While I know this is tue from my experience as a patent examiner, I performed a survey {using the PTO's Patent Application Information Retrieval (PAIR) system} of the 50 most recently issued patents classified in Class 435, Chemistry: Molecular Biology and Microbiology. In 76% of these patents, the examiner indicated in the first Office action that there was no allowable subject matter, i.e. none of the claims are patentable. Are the abilities of patent attorneys so low that over 75% of patent applications as filed do not contain at least one allowable claim? Or are the examiners writing "bogus" rejections? The answer is the latter.

Approval from US Patent and Trademark Office for InferX Corporation's patent application

InferX Corporation (OTC BB: IFRX.OB), which develops and markets enterprise software which performs privacy preserving predictive analysis on computer databases, revealed yesterday (8 July) that its patent, "Knowledge Inferencing and Data Visualization Method and System," has been approved by the US Patent and Trademark Office.

Dynamic Biometric Systems Announces That the US Patent Office Has Approved Claims 1 Through 15 of Patent #1; Receives an Order for 1,000 Bio-Pens and FINRA Has Approved Trading Status

Dynamic Biometric Systems Announces That the US Patent Office Has Approved Claims 1 Through 15 of Patent #1; Receives an Order for 1,000 Bio-Pens and FINRA Has Approved Trading Status

Non-Disruptive Backups and Migrations Enhances European Patent Protection and Management

The European Patent Office grants European patents. The EPO carries out searches and substantive examinations on a steadily rising number of European patent applications and international applications filed under the Patent Cooperation Treaty. The European Patent Office (EPO) needed to support up to 60 million patents documents and 800,000 patents within a high availability and ultra resilient DB2 environment. The European Patent Office deployed BMC DB2 solutions to more effectively support its customers and the management of its patent applications.

German Court Rules Qualcomm GSM Patent Claim Against Nokia Invalid

The German Federal Patent Court ruled today that Qualcomm’s GSM patent case against Nokia (NYSE: NOK) is invalid, Reuters reports. This is the third court to conclude that the American chipmaker’s patent claims against Nokia are “without merit,” said the Finnish handset maker. The United Kingdom High Court, and the U.S. International Trade Commission have also ruled that Qualcomm’s GSM patent claims against Nokia to be invalid. The two will meet again in German court in October, when a second Qualcomm (NSDQ: QCOM) patent case will be heard. The news comes on the same day that Qualcomm and Nokia are to meet in a Deleware Court over its ongoing patent dispute.

Mexens Technology (Navizon) receives patent for GPS/Wireless positioning

Mexens Technology, the maker of the Navizon software, yesterday announced that it has received a patent from the US Patent and Trademark Office for its "System and Method for Enabling Continuous Geographic Location Estimation for Wireless Computing Devices" (US Patent No. 7397424). The patent consists of a system combining GPS and Wireless signals (Wi-Fi and/or cellular) to determine a position. When GPS signal is not available then the system uses Wi-Fi or cellular triangulation.

Rim Semiconductor Files Patent Application

July 10, 2008 (FinancialWire) Rim Semiconductor Co. (OTCBB: RSMI) (Current Market Cap. US$356,698.00) filed a non-provisional patent application on its RQAM technology. Rim Semi s Cupria transport processor is based on this RQAM technology, and is able to drive data traffic at more than 40 megabits per second. Existing technologies are able to drive data 15 mbps at this distance on this wire type. The patent, titled Amplitude Modulation Decoder, was filed as a non-provisional patent with the United States Patent and Trademark Office. It was also filed under the Patent Cooperation Treaty. This protects Rim Semi s intellectual property rights across a wide geography. Other companies trading in Rim Semi s industry include ABB Ltd. (NYSE: ABB), Eaton Corp.

Search took 0.83 seconds.